MDNAF — Medicenna Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results
Canada's Medicenna narrows Q3 net loss, highlights MDNA11 efficacy
Brief: Medicenna Announces Changes To Board Composition
Brief: Medicenna Therapeutics Announces Key Program Updates And 2026 Outlook
Brief: Medicenna Therapeutics FY Net Income CAD 11.8 Million
Brief: Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
Brief: Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study
Brief: Medicenna Announces EMA Approval Of Its Clinical Trial Application To Expand Its Phase 1/2 Ability-1 Study To Europe
Brief: RA Capital Management Reports About 10% Passive Stake In Medicenna Therapeutics As Of April 30, 2024
Brief: Medicenna Therapeutics Announces CA$20 Million Investment From RA Capital Management
Brief: Medicenna Therapeutics Says 100% Reduction Of Target Lesions In 1 Melanoma & 1 Pancreatic Cancer Patient Observed Among 4 Partial Responses
Brief: Medicenna Presents Updated Results Of Single Agent MDNA11 Anti-Tumor Activity From Dose Escalation And Ongoing Dose Expansion Of The Phase 1/2 ABILITY-1 Study At The 2024 Annual Meeting Of The American Association For Cancer Research
Brief: Medicenna Therapeutics Reports Q3 Fiscal 2024 Financial Results
Brief: Medicenna Announces First Patient Dosed In ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA
Brief: Medicenna Commences Enrollment In The Ability-1 Study Combining MDNA11 With Pembrolizumab
Brief: Medicenna Announces Trading on the OTCQB Under the Symbol MDNAF